{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:17:17Z","timestamp":1788517037073,"version":"build-2803163510"},"reference-count":0,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"unspecified","delay-in-days":222,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2026]]},"abstract":"Abstract<\/jats:title>\n \n Background\/Objective<\/jats:title>\n Once-daily INGREZZA\u00ae (valbenazine), a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, is approved for tardive dyskinesia (TD) and Huntington\u2019s chorea. KINECT-PRO\u2122 (NCT05859698) is currently the only study to assess the effects of a VMAT2 inhibitor (valbenazine) on quality of life (QoL) and functionality in patients with TD using multiple validated patient-reported outcomes (PROs).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Adults with mild-to-severe TD movement severity (per Abnormal Involuntary Movement Scale [AIMS] item 8) and awareness of TD with mild-to-severe associated distress (per AIMS item 10) received open-label valbenazine (40, 60, or 80\u00a0mg) for 24\u00a0weeks. Primary endpoints included changes from baseline (CFBs) at Week 24 in 3 validated QoL\/functionality PROs: Tardive Dyskinesia Impact Scale (TDIS), the only psychometrically validated PRO developed specifically for TD; Sheehan Disability Scale (SDS); and EuroQoL Group\u2019s EQ-Visual Analogue Scale (EQ-VAS). Secondary endpoints included CFB in AIMS total score.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Substantial and clinically meaningful improvements in patient-reported QoL\/functionality and clinician-reported TD severity were observed throughout treatment with valbenazine in the overall study population and regardless of psychiatric diagnosis (mood disorders, psychotic disorders) or TD severity at baseline (mild, moderate\/severe). At Week 24 (\n N<\/jats:italic>\n \u00a0=\u00a045), mean CFBs were: TDIS (\u22128.0); SDS Social\/Leisure (\u22122.3); SDS Family\/Home (\u22121.6); EQ-VAS (+13.1); AIMS (\u22126.8). Previously established minimal clinically important difference (MCID) thresholds for TD were exceeded for TDIS and AIMS. Safety and tolerability were consistent with valbenazine\u2019s known profile.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n KINECT-PRO is the first study of its kind, and valbenazine is the only VMAT2 inhibitor to demonstrate QoL\/functional improvements in patients with TD across multiple validated PROs.<\/jats:p>\n <\/jats:sec>","DOI":"10.1017\/s1092852926101138","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T03:50:41Z","timestamp":1786420241000},"source":"Crossref","is-referenced-by-count":0,"title":["Valbenazine improves quality of life, functionality, and movement severity in patients with tardive dyskinesia: findings from the KINECT-PRO\u2122 study"],"prefix":"10.1017","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-5646","authenticated-orcid":false,"given":"Christoph U.","family":"Correll","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05vh9vp33","id-type":"ROR","asserted-by":"publisher"}],"name":"The Zucker Hillside Hospital"},{"id":[{"id":"https:\/\/ror.org\/01ff5td15","id-type":"ROR","asserted-by":"publisher"}],"name":"The Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell"},{"id":[{"id":"https:\/\/ror.org\/001w7jn25","id-type":"ROR","asserted-by":"publisher"}],"name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin"},{"id":[{"id":"https:\/\/ror.org\/00tkfw097","id-type":"ROR","asserted-by":"publisher"}],"name":"German Center for Mental Health (DZPG), Partner Site Berlin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Mercedes","family":"Perez-Rodriguez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"McEvoy","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/012mef835","id-type":"ROR","asserted-by":"publisher"}],"name":"Augusta University Medical College of Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David V.","family":"Sheehan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/032db5x82","id-type":"ROR","asserted-by":"publisher"}],"name":"University of South Florida Morsani College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9742-398X","authenticated-orcid":false,"given":"Gustavo","family":"Alva","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03nawhv43","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California Riverside Medical School"},{"id":[{"id":"https:\/\/ror.org\/05nmfef18","id-type":"ROR","asserted-by":"publisher"}],"name":"Hoag Hospital"},{"id":[{"id":"https:\/\/ror.org\/04pmrdd93","id-type":"ROR","asserted-by":"publisher"}],"name":"ATP Clinical Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Mathias","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0173ksf49","id-type":"ROR","asserted-by":"publisher"}],"name":"Health Outcomes Solutions"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Bron","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05d84mm26","id-type":"ROR","asserted-by":"publisher"}],"name":"Neurocrine Biosciences Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Farber","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05d84mm26","id-type":"ROR","asserted-by":"publisher"}],"name":"Neurocrine Biosciences Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05d84mm26","id-type":"ROR","asserted-by":"publisher"}],"name":"Neurocrine Biosciences Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Dunayevich","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05d84mm26","id-type":"ROR","asserted-by":"publisher"}],"name":"Neurona Therapeutics Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Parameswaran","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05d84mm26","id-type":"ROR","asserted-by":"publisher"}],"name":"Neurocrine Biosciences Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2026,8,11]]},"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852926101138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:01:06Z","timestamp":1788516066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852926101138\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"alternative-id":["S1092852926101138"],"URL":"https:\/\/doi.org\/10.1017\/s1092852926101138","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"e30"}}